## P-22 UNCOVERING INSIGHTS ON ACUTE VARICEAL HEMORRHAGE: A CROSS- COUNTRY SURVEY STUDY ON THE MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDING IN LATIN AMERICA

Jesus Ruiz<sup>1</sup>, Wagner Enrique Ramirez<sup>2</sup>, Antonio Olivas<sup>3</sup>, Luis Carlos Chávez<sup>1</sup>, Erick Jasso<sup>1</sup>, Josealberto S. Arenas<sup>1</sup>, Thamy Leidy Beltré<sup>4</sup>, Jose Carlos Jésus Ticona<sup>5</sup>, Karla Avendaño<sup>6</sup>, Venny Alberto Venegas<sup>1</sup>, Carlos Alonzo<sup>7</sup>, María Fernanda Vásquez<sup>8</sup>, Juanita Pérez<sup>9</sup>, Godolfino Miranda<sup>1</sup>, Graciela Castro<sup>1</sup>, Luis Eduardo Zamora<sup>1</sup>

Introduction and Objectives: Acute variceal hemorrhage (AVH) is a serious complication of portal hypertension and is associated with high mortality and high cost. Limited information exists regarding AVH management in Latin America (LATAM). This study aimed to gather data on AVH management and resource availability across LATAM. The goal was to bridge the knowledge gap, enhance medical attention, and optimize specialized care for patients with AVH in the region.

**Materials and Methods:** A survey was conducted using Microsoft Forms with recruitment via social media invitations and collaboration with local medical associations. It gathered data on demographics, clinical practices, and specialized resource availability. The LATAM countries were classified based on economic development (World Bank's classification system). Variables are described using percentages or medians and interquartile ranges and compared among socioeconomic regions using a chi-square test or analysis of variance as appropriate.

**Results:** In total, 798 respondents from 20 LATAM countries completed the survey. The median age was 39 years, with 80% attending specialists, 14% residents, and 6% fellows. Countries were represented by 6% high-income, 72% upper-middle income, and 21% lower-middle income populations. Gastroenterology (62%) was the predominant specialty, followed by internal medicine (23%), gastrointestinal endoscopy (18%), and hepatology (18%). Tertiary care centers accounted for 45% of the participants primary activities, followed by second-level care (30%) and private practice (21%). As for the existence of endoscopy suites, there were no differences between surveyed countries but their availability 24/7 remains higher in high income countries. The availability of vasoactive drugs correlated with economic development. The detailed findings are presented in Table 1.

**Conclusions:** In LATAM, the absence of standardized protocols, limited resources, and expertise pose challenges in AVH management. Enhancing access to specialized care and implementing standardized protocols is crucial to improve patient outcomes in the region.

Question surveyed	Answer	High income (n=47)	Medium High income (n=565)	Medium Low income (n=162)	Puerto Rico (n=15)	p*
Availability of endoscopy unit	Yes	44 (94%)	505 (89%)	152 (94%)	15 (100%)	0.2
Availability of endoscopy service 24/7	Yes	36 (77%)	287 (51%)	104 (64%)	10 (67%)	< 0.001
Routine correction of INR pre - endoscopic therapy	Yes	17 (36%)	210 (37%)	60 (37%)	7 (47%)	>0.9
Hemoglobin level threshold for indicating blood transfusion	7 g/dL	34 (72%)	473 (84%)	138 (85%)	13 (87%)	0.13
	8 g/dL	11 (23%)	72 (13%)	20 (12%)	2 (13%)	
	9 g/dL	1 (2.1%)	15 (2.7%)	1 (0.6%)	0 (0%)	
	10 g/dL	1 (2.1%)	5 (0.9%)	3 (1.9%)	0 (0%)	
Routine platelet for endoscopic band ligation when lower than 50x10*9 cells/L	Yes	15 (32%)	310 (55%)	96 (59%)	4 (27%)	0.01
Availability of vasoactive drugs (e.g. terlipressin, somatostatin, octeotride)	Yes	43 (91%)	443 (78%)	107 (66%)	15 (100%)	<0.001
Pharmacologic therapy before endoscopic therapy	Yes	30 (64%)	410 (73%)	108 (67%)	14 (93%)	0.003
Waiting time in hours in emergency department before endoscopic therapy	< 6 hours	18 (38%)	93 (16%)	21 (13%)	0 (0%)	
	6 - 12 hours	20 (43%)	241 (43%)	79 (49%)	8 (53%)	
	> 12 hours	8 (17%)	190 (34%)	55 (34%)	7 (47%)	

https://doi.org/10.1016/j.aohep.2023.101209

## P- 23 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: EPIDEMIOLOGY OF A COSTA RICAN COHORT

Francisco Vargas, María Lynch, María Castro, Aldo Carvajal, Esteban Cob, Victor Alvarado, Daniel Mondragón, Alejandra Ochoa, Bruno Solís, Vanessa López, Sheyla Araya, Irene Mora, Silvia Alfaro, Dionisio Flores, Allan Ramos-Esquivel, Gerardo Avendaño, Pablo Coste

Liver Unit, Hospital R.A. Calderón Guardia, Caja Costarricense del Seguro Social, San José, Costa Rica

**Introduction and Objectives:** Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide and a major problem in Latin America. It is characterized by significant epidemiological heterogeneity, but most data come from resource-rich countries. This is the largest cohort to date reporting HCC characteristics and outcomes in Central America.

**Materials and Methods:** Retrospective analysis of a cohort of HCC diagnosed radiographically or histologically and analysis of daily practice from a specialized Costa Rican center.

**Results:** From 10/2018 to 03/2023, 200 patients with HCC were evaluated. The median age at diagnosis was 67 years and 61% were men. The most common etiologies were NAFLD, alcohol, viral hepatitis, and autoimmune hepatitis (63, 22, 5 HBV, 4 HCV, and 3%, respectively), 67% had arterial hypertension, and 60% DM2. Diagnosis was 55% incidental (53% ultrasonography and 2% CT/MRI), 45% during surveillance (40% US, 3.5% CT/MRI and 1.5% AFP increase with negative US) and 42% had a significant elevation of AFP (20 ug/L). Child-Pugh Score was 54, 33 and 6% for A, B and C respectively and 7% were noncirrhotic (71% NAFLD). The modified BCLC staging system for HCC in cirrhotic liver was 3, 46, 17, 22, and 12% for stage 0, A, B, C, and D, respectively. Being diagnosed during surveillance was significantly associated with a curable BCLC stage (0 or A) (p=0.003) but not with better overall survival (p=0.18).

**Conclusions:** This study represents the largest cohort to date reporting HCC characteristics in Central America. Most HCCs are diagnosed incidentally and in a non-curable stage. Health policies should be directed based on the epidemiological factors identified in order to reduce the mortality of these patients.

<sup>&</sup>lt;sup>1</sup> Endoscopia Gastrointestinal, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Ciudad de México, México

<sup>&</sup>lt;sup>2</sup> Clínica Equilibrium, San Juan, Costa Rica

<sup>&</sup>lt;sup>3</sup> Department of Biostatistics, University of Washington, Washington, USA

<sup>&</sup>lt;sup>4</sup> Centro Médico Real Gastro-Metrics, Santo Domingo, República Dominicana

<sup>&</sup>lt;sup>5</sup> Gastroenterología Y Endoscopía Digestiva, Hospital Regional Honorio Delgado, Arequipa, Perú

<sup>&</sup>lt;sup>6</sup> Hospital Monte Sinaí, Guayaquil, Ecuador

<sup>&</sup>lt;sup>7</sup> Clínica Integra Medical Center, Guatemala, Guatemala

<sup>&</sup>lt;sup>8</sup> Gastroenterología y Endoscopia Digestiva, Universidad de Costa Rica, San José, Costa Rica

<sup>&</sup>lt;sup>9</sup> Gastroenterología, Hospital Juárez, Ciudad De México, México